Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing Ibrutinib-based Regimes

NCT04688385 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT04688385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04688385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IVAC-XS15-CLL01: Personalized Multi-peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing Ibrutinib-based Regimes
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1
Overall status
Completed
Start date
December 23, 2020
Completion date
October 17, 2024
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia